AVEO Pharmaceuticals — Corporate Update (May 2020)
25 slides from AVEO Pharmaceuticals's corporate update, May 29, 2020
Slide 1: TIVO-3 Overall Survival Update Conference Call
Passionately pursuing a better life for patients with cancer TIVO-3 Overall Survival Update Conference Call May 29, 2020 Exhibit 99.1
Slide 2: Cautionary Note Regarding Forward-Looking Statements
Cautionary Note Regarding Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained
Slide 3: Introductions and Agenda
Introductions Sumanta Kumar (Monty) Pal, M.D. Clinical Professor, Department of Medical Oncology & Therapeutics Research; Co-director, Kidney Cancer Program, City of Hope Cancer Center Michael Bailey, CEO Michael Needle, MD, CMO Erick Lucera, CFO Mike Ferraresso, SVP, Business Analytics and Commerci
Slide 4: Final OS analysis of phase 3 TIVO-3 study
TIVO-3: Final OS analysis of a phase 3, randomized, controlled, multi-center, open-label study to compare tivozanib to sorafenib in subjects with metastatic renal cell carcinoma (RCC) May 29, 2020
Slide 5: Clinical Context
TIVO-3: Clinical Context The treatment of patients with renal cell carcinoma (RCC) has advanced with the advent of anti-angiogenic drugs known as vascular endothelial growth factor receptor tyrosine kinase inhibitors (VEGFR TKI) Tivozanib is a highly potent and selective VEGFR TKI with a long half-l
Slide 6: Study Schema
TIVO-3: Study Schema N = 350 Recurrent/metastatic RCC ECOG PS 0 or 1 Failed at least two prior regimens including VEGFR-TKI Stratified by IMDC and prior regimen (TKI-TKI; TKI-CPI; TKI-Other) RANDOMIZE 1:1 Endpoints Primary: PFS Secondary: OS, ORR, DoR, Safety and Tolerability for ITT Randomized Tria
Slide 7: Patient Demographics
TIVO-3: Patient Demographics Characteristic Tivozanib (N=175) Sorafenib (N=175) Median age, years 62 64 Male 72% 73% IMDC prognostic risk Favorable 19% 21% Intermediate 62% 60% Poor 18% 19% ECOG performance status (0/1) (49% / 50%) (47% / 48%) Region (NA/EU) (18% / 82%) (15% / 85%) Prior Lines of Th
Slide 8: Met Primary Endpoint of PFS
TIVO-3: Met Primary Endpoint of PFS Primary PFS endpoint final analyses, Oct 4, 2018 Tivozanib 170 128 94 69 56 48 37 31 24 20 16 14 6 0 0 Sorafenib 159 116 65 42 27 18 11 9 5 3 3 2 2 0 0 1 yr PFS 28% 11% 18% 5% Tivozanib Sorafenib Subjects at risk Tivozanib N=170 Sorafenib N=159 Median, months (95%
Slide 9: Secondary Endpoint, ORR & DoR Statistically Significant Improvement vs Sorafenib
TIVO-3: Secondary Endpoint, ORR & DoR Statistically Significant Improvement vs Sorafenib Tivozanib Sorafenib ORR 18% 8% ORR p-value 0.02 Median DoR Not reached (12.9, NR) 5.7 months (5.6, NR) % Change in Target Lesion Longest Diameter Sum Response rate final analyses, Oct 4, 2018
Slide 10: Demonstrated Superior PFS & ORR in CPI Subgroup
TIVO-3: Demonstrated Superior PFS & ORR in CPI Subgroup Prior Checkpoint Inhibitor (CPI) + VEGFR TKI Tivozanib (n=47) Sorafenib (n=44) Sorafenib (n=44) Median PFS months (95% CI) 7.3 (4.8, 11.1) 5.1 (3.2, 7.4) 5.1 (3.2, 7.4) HR (95% CI) 0.55 (0.32, 0.94) P-value 0.028 ORR 24.4% 6.8% Porta et al. ASC
Slide 11: Treatment-Related Adverse Events
TIVO-3: Treatment-Related Adverse Events TRAEs ≥ 20% frequency in either arm* Tivozanib (N=173)^ Sorafenib (N=170)^ Preferred Term All Grades % Grade 3/4 % All Grades % Grade 3/4 % Treatment Related AEs 84 46 94 55 Hypertension 38 21 25 14 Diarrhea 33 2 50 9 Fatigue 29 4 19 5 Decreased Appetite 27 4
Slide 12: Dose Modifications
TIVO-3: Dose Modifications Characteristic Tivozanib (N=173)^ Sorafenib (N=170)^ Mean Number of Cycles Initiated 11.9 6.7 AEs Leading to Dose Reductions (%) 25 39 AEs Leading to Dose Interruption (%) 50 64 ADRs Leading to Permanent Discontinuation (%) 8 15 Treatment Related SAEs (%) 12 11 Treatment R
Slide 13: Final Overall Survival – May 2020
Final Overall Survival – May 2020 Tivozanib N=175 Sorafenib N=175 Median OS, months 16.4 19.2 HR (95% CI) 0.97 (0.75–1.25) p-value Stratified Log-rank 0.82 Tivozanib Sorafenib
Slide 14: Conclusions
Conclusions In this final analysis of survival in the TIVO-3 trial, tivozanib demonstrated clinically meaningful and statistically significant improvement in PFS with similar OS in patients with highly relapsed or refractory metastatic RCC Patients treated with a prior CPI and VEGFR TKI or 2 VEGFR T
Slide 15: Regulatory Update & Considerations
Regulatory Update & Considerations
Slide 16: Tivozanib New Drug Application
Tivozanib New Drug Application FDA dialogue actively proceeding NDA filed for R/R RCC March 31, 2020 Final OS data submitted as last component of the NDA Application Orientation Meeting (AOM) completed NDA submission is based on the TIVO-3 trial and supported by three additional trials Active compar
Slide 17: Positive Risk/Benefit Profile for Relapsed or Refractory RCC
Positive Risk/Benefit Profile for Relapsed or Refractory RCC Limited evidence for sequencing therapies in highly refractory RCC or after treatment with a checkpoint inhibitor TIVO-3 provides first Phase 3 dataset in a 3rd and 4th line patient population First large randomized study to evaluate treat
Slide 18: No VEGFR TKI Has Shown an OS Advantage Over Another in RCC
No VEGFR TKI Has Shown an OS Advantage Over Another in RCC Note: Data from separate studies 1) Hutson et al. Clinical Genitourinary Cancer; Vol. 15, No. 1, 72-6. 2) Choueiri et al. European Journal of Cancer 2018; 94: 115e125 3) Motzer et. al. Lancet Oncol 2013; 14: 552–62. 4) Motzer, et al. N Engl
Slide 19: Commercial Opportunity
Commercial Opportunity A/=O ONCOLOGY C dfernalk
Slide 20: Significant Potential Commercial Opportunity for Tivozanib in the United States
If Approved, Significant Potential Commercial Opportunity for Tivozanib in the United States 2nd Line Market (est. 2020) ~$700M1 NA royalties to KHK are low- to mid-teens on net sales Extended OS from IO may expand population eligible for 3rd line treatment 2 1 >PFS with tivozanib may extend treatme
Slide 21: Potential Relevance of Tivozanib in Refractory RCC
Potential Relevance of Tivozanib in Refractory RCC Source: AVEO blinded Third-Party U.S. Oncologist Market Research using approximate TIVO-3 PFS and AE profile - Dec 2018 n=100 Treatments with proven efficacy are needed for patients who have failed 2 or more lines of treatment for RCC I prefer using
Slide 22: Tivozanib Properties May Provide Advantages in Combination with IO Therapy
Nakamura K et al. Cancer Res 2006;66:9134–9142. Pawlowski N et al. AACR 2013. Poster 3971. Hammers, Emerging VEGF-I/O Combinations, ASCO 2017 Tivozanib Properties May Provide Advantages in Combination with IO Therapy A Phase 1/2, Open-Label, Multi-Center Study of Tivozanib in Combination with Nivolu
Slide 23: Summary
Summary FDA dialogue actively proceeding NDA filed for R/R RCC March 31, 2020 Application Orientation Meeting (AOM) completed Tivozanib is well positioned for the changing R/R RCC landscape R/R RCC is a significant monotherapy market opportunity: $1b and growing TIVO-3 is the first positive Phase 3
Slide 24: Q&A
Q&A M=O ONCOLOGY
Slide 25: TIVO-3 Overall Survival Update Conference Call
Passionately pursuing a better life for patients with cancer TIVO-3 Overall Survival Update Conference Call May 29, 2020